Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Kura Oncology announced that updated Phase 1a results from the FIT-001 study evaluating darlifarnib combined with cabozantinib in advanced renal cell carcinoma will be presented at the 2026 Kidney Cancer Research Summit. The long-term follow-up data provides further evidence supporting darlifarnib’s potential to enhance VEGFR-targeted therapies in cabozantinib-naïve patients.
Key figures
- Drug Name
- darlifarnib
- Phase Of Trial
- Phase 1a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.